Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hanefeld

Showing results (141-150 of 224) with videos related to

Pageof 23
Sort By:
European Heart Journal|December 20, 2003
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studiesM Hanefeld, M Cagatay, T Petrowitsch, et al.
Annals of Clinical Research|January 1, 1988
More exercise for the hyperlipidaemic patients?M Hanefeld, S Fischer, U Julius, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|March 25, 2005
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trialB H Charbonnel, D R Matthews, G Schernthaner, et al.
Diabetes/Metabolism Research and Reviews|September 24, 2004
Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative studyD R Matthews, B H Charbonnel, M Hanefeld, et al.
European Journal of Internal Medicine|March 15, 2002
Insulin resistance and metabolic parameters in type 2 diabetic patientsW Metzler, S Fischer, C Köhler, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 16, 2010
Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetesM Hanefeld, C Koehler, C Hoffmann, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|June 17, 1998
Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitusM Breidert, T Temelkova-Kurktschiev, M Hanefeld, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|December 9, 2008
Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetesF Pistrosch, F Schaper, J Passauer, et al.
Biomedica Biochimica Acta|January 1, 1988
Is the level of steroid hormones in the low density lipoprotein (LDL) particles responsible for the prostaglandin I2 inhibitory potency of LDL?J Beitz, K Schollberg, S Fischer, et al.
Arzneimittel-Forschung|December 1, 1988
Effects of a bezafibrate sustained release formulation on plasma lipoproteins in patients with hypercholesterolemia. Importance of timing of tablet intake for efficacyM Hanefeld, P D Lang, S Fischer, et al.
Pageof 23

Showing results (141-150 of 224) with videos related to

Sort By:
Pageof 23
European Heart Journal|December 20, 2003
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studiesM Hanefeld, M Cagatay, T Petrowitsch, et al.
Annals of Clinical Research|January 1, 1988
More exercise for the hyperlipidaemic patients?M Hanefeld, S Fischer, U Julius, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|March 25, 2005
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trialB H Charbonnel, D R Matthews, G Schernthaner, et al.
Diabetes/Metabolism Research and Reviews|September 24, 2004
Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative studyD R Matthews, B H Charbonnel, M Hanefeld, et al.
European Journal of Internal Medicine|March 15, 2002
Insulin resistance and metabolic parameters in type 2 diabetic patientsW Metzler, S Fischer, C Köhler, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 16, 2010
Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetesM Hanefeld, C Koehler, C Hoffmann, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|June 17, 1998
Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitusM Breidert, T Temelkova-Kurktschiev, M Hanefeld, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|December 9, 2008
Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetesF Pistrosch, F Schaper, J Passauer, et al.
Biomedica Biochimica Acta|January 1, 1988
Is the level of steroid hormones in the low density lipoprotein (LDL) particles responsible for the prostaglandin I2 inhibitory potency of LDL?J Beitz, K Schollberg, S Fischer, et al.
Arzneimittel-Forschung|December 1, 1988
Effects of a bezafibrate sustained release formulation on plasma lipoproteins in patients with hypercholesterolemia. Importance of timing of tablet intake for efficacyM Hanefeld, P D Lang, S Fischer, et al.
Pageof 23